Skip to main content
OpenTrials
Completed

NCT Number: NCT07386613

Feasibility of Home Monitoring of Visual Function in DR

Diabetes is a serious condition where patients can develop complications in their body including their eyes which can lead to sight loss. Patients with diabetes are encouraged to attend yearly screening appointments at which signs of Diabetic Retinopathy (DR) are assessed. Attendance at these appointments and at any follow-up appointments can be time-consuming and inconvenient for those working. Better ways to monitor changes in vision are needed. Therefore, we are hoping to develop a set of eye tests that a person with diabetes can complete at home on a smartphone in collaboration with researchers at OKKO Health.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes (DM) Cardiovascular Diseases Diabetes (Insulin-requiring, Type 1 or Type 2) Diabetes Complication Diabetes Complications Diabetes Mellitus Diabetes Pregnancy Diabetes, Gestational Diabetic Angiopathies Diabetic Retinopathy Diabetic Retinopathy (DR) Dialysis Patients Endocrine System Diseases Eye Diseases Female Urogenital Diseases and Pregnancy Complications Gestational Diabetes Mellitus in Pregnancy Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Pregnancy Complications Retinal Diseases Urogenital Diseases Vascular Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Belfast Health and Social Care Trust, Belfast City Hospital, Belfast, Belfast City, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Study 1:

  • The 55 participants with Type 1 or Type 2 diabetes must also be a gestational, or dialysis DR patient.
  • Aged 18-70.
  • All participants should have access to one of the following devices on a daily basis: iPhone (X, XS, XR, 11, 11 Pro, 11 Pro Max, SE 2020, 12, 12 Pro, 12 Pro Max, 12 mini); iPad (Pro 11-inch 2nd generation, Pro 12.9-inch 4th generation); Samsung Galaxy S8, S9, S10, A20e or A40; Samsung Galaxy Tab S3; Honor 10 Lite; Motorola G6 or G7 Power or Pixel 3a.
  • All participants should also have the ability to read and understand in English and be able to give informed consent.
  • All participants should also be able to tap the screen of a digital device.
  • All gestational and dialysis participants should be willing to undergo handheld retinal imaging, no pupil dilation is required.
  • Be willing to use the app from home for up to 6 months in between the participant's regular clinic visits.

Study 2:

  • The 35 participants with type 1 or type 2 diabetes should have R0 no retinopathy or R1 background changes (this is stated on the letter they receive from the Diabetic Retinal Screening service).
  • Participants must already have a diabetic screening letter dated within 3 months and use a continuous glucose monitor and be willing to share the data from their monitor with the study team. They must also be willing to allow the research team access to their most recent OCT scans which will be accessed by Prof Tunde Peto.
  • All participants should have access to one of the following devices on a daily basis: iPhone (X, XS, XR, 11, 11 Pro, 11 Pro Max, SE 2020, 12, 12 Pro, 12 Pro Max, 12 mini); iPad (Pro 11-inch 2nd generation, Pro 12.9-inch 4th generation); Samsung Galaxy S8, S9, S10, A20e or A40; Samsung Galaxy Tab S3; Honor 10 Lite; Motorola G6 or G7 Power or Pixel 3a.
  • All participants should also have the ability to read and understand in English and be able to give informed consent.
  • All participants should also be able to tap the screen of a digital device

Exclusion criteria

Study 1 and 2:

  • The presence of another ocular disease that impacts vision such as age-related macular degeneration, glaucoma, or active uveitis.
  • Participants who are unable to tap a screen.
  • Serious life-threatening conditions that would preclude attendance in the longitudinal part of the study.
  • Neurological conditions that can impair vision
  • Any physical limitation that would make the participant unable to attend clinic visits (e.g., patients with arthritis or neck problems who may be unable to sit for a prolonged period of time).

Treatment and study plan

Okko Health App

Device

Okko Health digital health app used to assess visual acuity and contrast sensitivity using a mobile phone.

Primary outcomes

  1. Primary Outcome : Explore the feasibility of longitudinal monitoring in hard-to-reach clinical populations by analysing recruitment and retention data, frequency of testing, and factors influencing play frequency and sustained engagement with the app.

    Time frame: 6 months

    Assessment of feasibility

    Feasibility was assessed using recruitment, retention and engagement data from the Dialysis, Pregnancy and CGM high risk groups. Attrition rates from verbal agreement to signed consent and study completion were documented and reasons for dropout were captured through research team notes, participant self-report and follow-up communication.

    Engagement was quantified as the number of OKKO Health app plays over 6 months for each eye in the OKKO Circles Acuity (LogMAR) and the OKKO Contrast Sensitivity (LogCS) games. Participants were requested to play both games at least once a week. The app automatically logged usage data, including total plays and plays per eye.

Secondary outcomes

  1. Secondary Outcome: Explore the acceptability of longitudinal monitoring in populations at risk of DR that are hard to reach through qualitative and interview data.

    Time frame: 6 months

    This study utilized both quantitative and qualitative data to assess acceptability and adherence including The Adherence and Acceptability Questionnaire (AAQ) (adapted from Venkatesh et al., 2003) and The Ease of Use and Acceptability Questionnaire (EUAQ) (modified from Tay et al., 2004).

    The adapted 16-item AAQ asked participants questions about their experience regarding five dimensions or aspects of the app: perceived usefulness, perceived ease of use, adherence, behavioural intention and digital system accessibility. For example, the AAQ questionnaire began with the following statement: "I think that using digital health interventions to monitor my vision weekly could be a good thing". Participants then rated this statement in relation to their experience of using the OKKO Health app on a five-point Likert scale, ranging from 1: 'Strongly Disagree' to '5: 'Strongly Agree'.

Other outcomes

  1. 3. Third Outcome Measure: Describe the challenges associated with implementing longitudinal home-based monitoring in high-risk populations, identifying key logistical, behavioural, and technological barriers to engagement.

    Time frame: 6 months

    Given the study's exploratory nature and the lack of suitably developed instruments, open-ended survey questions were added to the adapted EUAQ (Tay et al. 2004). These were administered to capture patients' experiences and potential challenges using the OKKO Health app. They began with the question, 'Did you find the tests easy to do? If no- How?'. This question was followed by a list of seven items such as: 'Did you find any of the tests particularly difficult?'; 'Which was your favourite test? Why?'; 'If you knew you had to continue to carry out these tests for a longer period of time would you be willing to continue?'. A multi-line text entry field was implemented in Qualtrics, which allowed participants responses up to five lines. An analysis of the answers to these questions aided the exploration of challenges to. Implementation. In addition to the open-ended questionnaire responses, supplementary qualitative feedback was recorded using multiple sources, through entries in the r

Sponsors and collaborators

Lead sponsor

Queen's University, Belfast

Other

Collaborators

  • OKKO Health

Registry information

Official study title

Investigating the Feasibility of Home Monitoring of Visual Function in Populations at High Risk of Developing Diabetic Retinopathy (DR) Using Novel Game-based Technology (OKKO Health)

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Feb 4, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.